Information Provided By: 
Fly News Breaks for September 11, 2017
TSRO
Sep 11, 2017 | 05:55 EDT
Citi analyst Robyn Karnauskas says the early safety and preliminary efficacy data from Tesaro's PD-1 molecule, TSR-042, look promising and comparable to existing PD-1s. The drug showed early anti-tumor activity, in-line with expectations, Karnauskas tells investors in a research note. She believes, however, that investors are likely to wait for durable data from larger patient population before assigning value to TSR-042. The analyst keeps a Buy rating on Tesaro with a $216 price target.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
